Shingrix in Kidney Transplant Recipients

This study is looking at how well the shingles vaccine, Shingrix, works and how safe it is for adults with kidney failure who are waiting for a kidney transplant. It also wants to see if an extra dose of Shingrix after a transplant can improve protection. Researchers will measure your body's immune response to the vaccine at different times over 12 months after vaccination. You might be able to join if you are 18 to 70 years old, have chronic kidney failure, and are on a waiting list for a kidney transplant. The study aims to enroll 132 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 132 participants.
What's involved
Participants will receive the standard Shingrix vaccine. The study will measure your immune response at 12 months after vaccination.
Compensation
Not stated in the trial record.
Follow-up
Your immune response will be measured at 12 months after vaccination.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04128189

Shingrix in Renal Transplant Recipients

Recruiting
PHASE3Ages 18–70InterventionalTreatment
University of Colorado, Denver
~132 participants
Updated 2026-04-08 on ClinicalTrials.gov
What's tested:Shingrix

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
gE-Specific IL-2 T Cell Response at 12 Months After Randomization
Measured over 12 months after vaccination
Kidney Transplant Recipient Response to Shingrix Vaccine
Kidney Failure
Kidney Failure, Chronic
Kidney Transplantation
Herpes Zoster (HZ)
4 sites across 4 states
Colorado1
Georgia1
Massachusetts1
Texas1
  • Myron J Levin, MD · PRINCIPAL_INVESTIGATOR · University of Colorado Anschutz School of Medicine

Opens a ready-to-send draft in your own email app — review before sending.

  • gE-Specific IL-2 T Cell Response at 12 Months After Randomization12 months after vaccination

    1\. gE-Specific IL-2 T Cell Response at 12 Months After Randomization Description: Cellular immune response measured by gE-specific IL-2-producing spot-forming cells (SFC) per 10⁶ peripheral blood mononuclear cells (PBMC) using FluoroSpot assay in renal transplant recipients. Comparison between participants who receive a third dose of Shingrix post-transplant and those who do not receive a third dose. Time frame: 12 months after vaccination (post-transplant)